BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35695125)

  • 1. Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
    Yu G; Lu W; Chen X; Li Y; Long J; Zheng Z; Yin C; Xu D
    Leuk Lymphoma; 2022 Nov; 63(11):2604-2615. PubMed ID: 35695125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
    Pierson BA; Miller JS
    Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
    Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
    Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
    Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
    Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
    Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
    Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
    Cancer Sci; 2020 Aug; 111(8):2923-2934. PubMed ID: 32614159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
    Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
    J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
    Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
    Front Immunol; 2018; 9():2433. PubMed ID: 30405627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of Costimulatory Molecule Tim3 on NK Cells and Its Subsets in Patients with Acute Myeloid Leukemia].
    Wu WH; Shao JW; Jiang YL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1899-1903. PubMed ID: 33283717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 Diabetes.
    Gomez-Muñoz L; Perna-Barrull D; Villalba A; Rodriguez-Fernandez S; Ampudia RM; Teniente-Serra A; Vazquez F; Murillo M; Perez J; Corripio R; Bel J; Vives-Pi M
    Front Immunol; 2020; 11():611522. PubMed ID: 33569058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.
    Sanchez MB; Vasconcelos Cordoba B; Pavlovsky C; Moiraghi B; Varela A; Custidiano R; Fernandez I; Freitas MJ; Ventriglia MV; Bendek G; Mariano R; Mela Osorio MJ; Pavlovsky MA; García de Labanca A; Foncuberta C; Giere I; Vera M; Juni M; Mordoh J; Sanchez Avalos JC; Levy EM; Bianchini M
    Front Immunol; 2023; 14():1241600. PubMed ID: 37818372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
    Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C
    Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ureshino H; Shindo T; Tanaka H; Saji H; Kimura S
    Mol Cancer Ther; 2021 Jan; 20(1):142-149. PubMed ID: 33082274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
    Huuhtanen J; Adnan-Awad S; Theodoropoulos J; Forstén S; Warfvinge R; Dufva O; Bouhlal J; Dhapola P; Duàn H; Laajala E; Kasanen T; Klievink J; Ilander M; Jaatinen T; Olsson-Strömberg U; Hjorth-Hansen H; Burchert A; Karlsson G; Kreutzman A; Lähdesmäki H; Mustjoki S
    Leukemia; 2024 Jan; 38(1):109-125. PubMed ID: 37919606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
    Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD56
    Chen T; Liu C; Li L; Liu H; Wang T; Shao Z; Fu R
    Int J Lab Hematol; 2019 Jun; 41(3):353-363. PubMed ID: 30779419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-frequency, exhausted immune status of CD56
    Pan Z; Zhao R; Shen Y; Liu K; Xue W; Liang C; Peng M; Hu P; Chen M; Xu H
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108369. PubMed ID: 34844872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
    Ureshino H; Shindo T; Sano H; Kubota Y; Ando T; Kidoguchi K; Kusaba K; Itamura H; Kojima H; Kusunoki Y; Miyazaki Y; Kojima K; Tanaka H; Saji H; Oshima K; Kimura S
    Int J Hematol; 2020 May; 111(5):733-738. PubMed ID: 31873846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allelic polymorphisms of
    Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
    Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.